They selected lower CRP cut-offs to guide prescribing for (more) severe RTIs (e.g., exacerbated COPD) and higher CRP cut-offs for uncomplicated RTIs (e.g., healthy individuals with cough). The gene discussed is CRP; the disease is chronic obstructive pulmonary disease.